Agile Therapeutics Announces The Availability Of Twirla To MMCAP Infuse Members Effective July 1
Portfolio Pulse from Benzinga Newsdesk
Agile Therapeutics announced that Twirla, a transdermal system, will be available to MMCAP Infuse members nationwide starting July 1, 2023. This is expected to boost non-retail channel growth and contribute to 2023 net revenue of $25-$30 million.
June 26, 2023 | 12:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Agile Therapeutics' Twirla availability to MMCAP Infuse members is expected to boost non-retail channel growth and contribute to 2023 net revenue of $25-$30 million.
The availability of Twirla to MMCAP Infuse members, which has over 26,000 member facilities in all 50 states, will likely increase the product's reach and sales. This is expected to contribute to Agile Therapeutics' 2023 net revenue target of $25-$30 million, positively impacting the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100